Herantis Pharma: Phase 1/2 CDNF Topline Results

Herantis Pharma: Phase 1/2 CDNF Topline Results
We are delighted that Finnish-based Herantis Pharma Plc have announced that their ongoing Phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint of safety and tolerability. In pre-clinical studies, CDNF has been shown to have a protective impact on pathways involved in Parkinson’s, preventing neurons from ... read more
Source: The Cure Parkinson’s TrustPublished on 2020-02-26